Key Points
- CEO John C.M. Farquhar sold 32,676 Heartflow shares at an average price of $45, generating $1.47 million. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his direct ownership by 7.77% to 388,044 shares.
- Heartflow reported quarterly revenue of $64.08 million, up 47.7% year over year, and an EPS loss of $0.07 that beat analyst expectations. The company remains unprofitable, with a negative net margin of 55.82%.
- Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $43.43, while HTFL recently traded near its 52-week high at $46.80.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 32,676 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $45.00, for a total transaction of $1,470,420.00. Following the completion of the sale, the chief executive officer directly owned 388,044 shares of the company's stock, valued at approximately $17,461,980. This trade represents a 7.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Friday, August 14th, John C.M. Farquhar sold 15,560 shares of Heartflow stock. The stock was sold at an average price of $39.06, for a total transaction of $607,773.60.
- On Monday, August 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.31, for a total transaction of $638,730.22.
- On Friday, July 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.75, for a total transaction of $626,095.50.
- On Wednesday, June 24th, John C.M. Farquhar sold 38,900 shares of Heartflow stock. The shares were sold at an average price of $35.00, for a total value of $1,361,500.00.
- On Wednesday, June 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $28.50, for a total value of $643,017.00.
Heartflow Price Performance
NASDAQ:HTFL opened at $46.80 on Friday. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $47.95. The company has a 50-day moving average of $30.33 and a 200 day moving average of $28.17. The firm has a market cap of $4.07 billion and a PE ratio of -25.57.
Heartflow (NASDAQ:HTFL - Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business had revenue of $64.08 million for the quarter. Heartflow's revenue for the quarter was up 47.7% on a year-over-year basis. Sell-side analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of HTFL. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow in the fourth quarter valued at approximately $27,000. Russell Investments Group Ltd. acquired a new position in shares of Heartflow during the fourth quarter worth $45,000. Essential Partners LLC purchased a new stake in shares of Heartflow during the 1st quarter valued at $57,000. Legal & General Group Plc acquired a new stake in shares of Heartflow in the 3rd quarter worth $59,000. Finally, Strs Ohio purchased a new position in Heartflow during the 4th quarter worth $99,000.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on HTFL shares. Morgan Stanley boosted their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock an "equal weight" rating in a research note on Friday, August 14th. Canaccord Genuity Group increased their target price on Heartflow from $37.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, August 14th. Freedom Capital upgraded Heartflow to a "strong-buy" rating in a report on Tuesday, June 30th. Benchmark restated a "buy" rating on shares of Heartflow in a research note on Friday, August 14th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $45.00 price objective (up from $38.00) on shares of Heartflow in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.43.
Get Our Latest Analysis on HTFL
About Heartflow
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
